Boston Scientific to Acquire Penumbra, Inc. in New Agreement
Boston Scientific Corporation has announced its agreement to acquire Penumbra, Inc. This move will significantly bolster Boston Scientific’s cardiovascular portfolio.
Overview of the Acquisition
On January 15, 2026, Boston Scientific confirmed the acquisition of Penumbra in a cash and stock deal. The transaction values Penumbra stock at $374 per share, totaling approximately $14.5 billion.
Strategic Importance
- This acquisition allows Boston Scientific to enter fast-growing segments in the vascular space.
- The deal underscores Boston Scientific’s commitment to addressing the rising prevalence of vascular diseases.
Leadership Insights
Mike Mahoney, CEO of Boston Scientific, expressed excitement about integrating Penumbra’s innovative technologies and talented team into their operations. He indicated that Penumbra’s addition would enhance patient access to cutting-edge medical solutions.
Adam Elsesser, CEO of Penumbra, emphasized the importance of their combined expertise to improve patient care outcomes. Upon completion of the acquisition, Elsesser is expected to join Boston Scientific’s board of directors.
Significance of Vascular Health
Cardiovascular diseases remain a leading cause of mortality globally, affecting millions. Penumbra’s advanced technologies aim to combat conditions such as pulmonary embolism, stroke, and deep vein thrombosis.
Penumbra’s Innovative Portfolio
- Mechanical thrombectomy devices, including Lightning Bolt® and Lightning Flash® systems.
- A peripheral embolization system to manage hemorrhaging.
- Neurovascular solutions for stroke treatment and access.
Financial Projections and Structure
For Q4 2025, Penumbra anticipates revenue growth between 21.4% to 22.0%. Additionally, they expect around $1.4 billion in total revenue for the full year, reflecting a growth rate of 17.3% to 17.5% compared to the previous year.
According to the terms, stockholders can opt for either cash or shares of Boston Scientific common stock. The deal outlines a financing strategy, with approximately $11 billion allocated for the cash component through existing cash reserves and new debt issuance.
Future Outlook
The deal is predicted to be slightly dilutive to earnings in the first year, becoming neutral to accretive in subsequent years. Completion of the transaction is anticipated in 2026, pending stockholder approval and customary closing conditions.
Boston Scientific has prepared to discuss this acquisition in more detail in a conference call scheduled for today at 8:00 a.m. ET.
